Enliven Therapeutics
ELVN
ELVN
62 hedge funds and large institutions have $541M invested in Enliven Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0.13% less ownership
Funds ownership: 94.96% → 94.83% (-0.13%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Holders
62
Holding in Top 10
4
Calls
–
Puts
–
Top Buyers
| 1 | +$20.6M | |
| 2 | +$3.9M | |
| 3 | +$1.84M | |
| 4 |
Morgan Stanley
New York
|
+$1.73M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.09M |
Top Sellers
| 1 | -$16.6M | |
| 2 | -$14.3M | |
| 3 | -$369K | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$245K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$177K |